SCOUT-HCM data show LVOT gradient reductions persisted, patients switching from placebo responded similarly, and no patient had LVEF below 50%.
|Articles|April 29, 2022
5 Key Sessions and Interviews at Asembia 2022 Specialty Pharmacy Summit
Stay tuned at PharmacyTimes.com for exclusive session coverage and interviews with experts.
Advertisement
Pharmacy Times will be covering the 2022
The summit will include expert speakers, business sessions, exhibits, and a featured keynote address from Scott Gottlieb, MD, former FDA commissioner from 2017 to 2019. Stay tuned at PharmacyTimes.com for exclusive session coverage and interviews with experts, including:
- Learn more about pharmacists’ role in driving biosimilar adoption in a conversation with
Sonia Oskouei, PharmD , vice president of biosimilars at Cardinal Health. Oskouei is presenting a session on May 2, titled “Will Pharmacists Play a Bigger Role in Driving Biosimilar Adoption in 2023 and Beyond?” - On May 2, Pharmacy Times will be covering a session titled “Navigating the Pandemic with EUA Therapies,” about how Emergency Use Authorization (EUA) therapies have impacted the COVID-19 landscape. According to presenters, the COVID-19 pandemic and the EUA system offers novel opportunities for specialty pharmacy interventions.
- On May 4, a session titled “Pharmacist Evolution: A New More Active Role from Patient-Reported Outcomes to Developing Insights” will discuss how specialty pharmacists are key in optimizing complex treatment decisions. By using both data and patient-reported outcomes, specialty pharmacies can help the health system adapt to an increasingly complex environment.
- Ray Tancredi, divisional vice president of specialty pharmacy, development and brand Rx/vaccine purchasing at Walgreens, will discuss his presentation on the specialty pharmaceutical pipeline. Specifically, Tancredi will address which approvals pharmacists should be aware of on the horizon.
- Finally, stay tuned on May 3 to learn about new models in specialty drug management from the session titled “Quality, Equity, and Affordability: Employers, Change, and New Models for Specialty Management.” In this session, panelists will discuss what employers are seeing in the marketplace both from pharmacy benefit managers and potential vendors in relation to specialty spending.
Stay tuned on PharmacyTimes.com and follow Pharmacy Times on social media for exclusive, live coverage and the latest updates!
Advertisement
Related to this article
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
At SITC 2026, 10 of 15 patients with advanced melanoma responded to investigational amsokigene autoleucel at the recommended phase 2 dose, with 5 still in response 12 months after infusion.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
If gene therapies are expected to deliver decades of benefit, long-term evidence collection must be coordinated, useful to patients, and financially sustainable.
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
2
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
3
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5